Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Spanish study gives reassurance: small HIV blips do not predict treatment failure

A very low viral load (20-49 copies/ml) during HIV therapy does not increase the risk of the subsequent virological failure of treatment (viral load above 200 copies/ml), according

Published
21 September 2016
By
Michael Carter
Targeting dormant HIV

Why wake up the virus? To better kill it, of course. A team from the University of Montreal Hospital Research Centre (CRCHUM) has taken an important step forward in the search for a HIV/AIDS cure. The laboratory of Dr. Daniel Kaufmann has developed a highly accurate technique for detecting the rare cells that hide the virus and prevent current therapies from curing HIV infection.

Published
20 September 2016
From
HIV / AIDS News From Medical News Today
Four day a week ART: sub-optimal drug levels but few virological failures

A poster at IAS 2016 reported on the effectiveness of a strategy in France to use reduced dose maintenance therapy. This involved only taking ART for four rather than seven days a week.

Published
20 September 2016
From
HIV i-Base
Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

Published
20 September 2016
From
BETA blog
Janssen Submits Marketing Authorisation Application for Darunavir-Based Single Tablet Regimen for Treatment of HIV-1 to European Medicines Agency

If approved, this tablet would be the first protease inhibitor-based STR option indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adults and adolescents. This new treatment would combine the protease inhibitor, darunavir (DRV, D, 800 mg), with the pharmacokinetic enhancer, cobicistat (COBI, C, 150 mg) and the nucleoside reverse transcriptase inhibitors emtricitabine (FTC, F, 200 mg) and tenofovir alafenamide (TAF 10 mg), in one single tablet.

Published
13 September 2016
From
Janssen-Cilag press release
Delays in updating HIV treatment guidelines in Africa blocking early treatment for millions

Delays in adopting the World Health Organization (WHO) 2015 recommendation of HIV treatment for all threaten the achievement of the 90-90-90 targets for HIV diagnosis and viral

Published
12 September 2016
By
Keith Alcorn
Evidence that “on-demand” PrEP taken before and after sex can prevent HIV

How many doses of Truvada-based PrEP (pre-exposure prophylaxis) are needed to provide adequate protection against HIV? Might it be possible to take PrEP only before and after sex—instead of every day?

Published
12 September 2016
From
BETA blog
Why 2.1 million Indians infected with HIV do not get the drugs they need

Each of an estimated 2.1 million Indians infected with the human immunodeficiency virus (HIV) should be getting a cocktail of drugs to prolong their lives and reduce infections, but no more than 44% do, the minister of health told the Lok Sabha (parliament’s lower house) in April 2016.

Published
12 September 2016
From
Firstpost
A British Film Festival Has Withdrawn A Documentary That Denies HIV/Aids Exists

The Portobello Film Festival in London was to air Positive Hell, which claims the entire medical establishment is wrong about HIV/AIDS, this weekend.

Published
08 September 2016
From
BuzzFeed News
Life expectancy of people starting HIV therapy differs sharply between high- and middle/low-income countries

There are significant disparities in the life expectancy of HIV-positive people starting combination antiretroviral therapy (cART) between world regions, according to the results of a meta-analysis published in

Published
08 September 2016
By
Michael Carter
← First12345...425Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close